Premium
SAFETY RUN‐IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN'S LYMPHOMA
Author(s) -
Gerecitano J.,
Santoro A.,
Leppä S.,
Kim T.,
Kim W.,
Janssens A.,
Pedersen M.,
Reis D.,
Granvil C.,
Shen J.,
Zheng H.,
Childs B.H.,
Zinzani P.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_187
Subject(s) - bendamustine , medicine , rituximab , obinutuzumab , tolerability , follicular lymphoma , idelalisib , ofatumumab , oncology , gastroenterology , lymphoma , adverse effect , chronic lymphocytic leukemia , leukemia , ibrutinib